PAVmed Inc. (PAVM)

Market Cap	13.29M +38.4%
Revenue (ttm)	112,000 -89.0%
Net Income	-20.63M
EPS	-9.85
Shares Out	6.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,027
Open	1.891
Previous Close	1.950
Day's Range	1.890 - 1.940
52-Week Range	1.840 - 28.440
Beta	0.70
Analysts	Buy
Price Target	36.50 (+1,821.05%)
Earnings Date	Nov 13, 2026

About PAVM

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 28, 2016
• Employees: 41
• Stock Exchange: Nasdaq
• Ticker Symbol: PAVM
• Website: https://www.pavmed.com

Analyst Summary

According to 2 analysts, the average rating for PAVM stock is "Buy." The 12-month stock price target is $36.5, which is an increase of 1,821.05% from the latest price.

Price Target

$36.5

(1,821.05% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 2, 2026

Data Sources Report a data error